Neoadjuvant chemotherapy in breast cancer induces miR-34a and miR-122 expression

[en] Circulating microRNAs (miRNAs) have been extensively studied in cancer as biomarkers but little is known regarding the influence of anti-cancer drugs on their expression levels. In this article, we describe the modifications of circulating miRNAs profile after neoadjuvant chemotherapy (NAC) for breast cancer. The expression of 188 circulating miRNAs was assessed in the plasma of 25 patients before and after NAC by RT-qPCR. Two miRNAs, miR- 34a and miR-122, that were significantly increased after NAC, were measured in tumor tissue before and after chemotherapy in 7 patients with pathological partial response (pPR) to NAC. These 2 chemotherapy-induced miRNAs were further studied in the plasma of 22 patients with adjuvant chemotherapy (AC) as well as in 12 patients who did not receive any chemotherapy. Twenty-five plasma miRNAs were modified by NAC. Among these miRNAs, miR-34a and miR-122 were highly upregulated, notably in pPR patients with aggressive breast cancer. Furthermore, miR-34a level was elevated in the remaining tumor tissue after NAC treatment. Studying the kinetics of circulating miR-34a and miR-122 expression during NAC revealed that their levels were especially increased after anthracycline-based chemotherapy. Comparisons of the plasma miRNA profiles after NAC and AC suggested that chemotherapy-induced miRNAs originated from both tumoral and non-tumoral compartments. This study is the first to demonstrate that NAC specifically induces miRNA expression in plasma and tumor tissue, which might be involved in the anti-tumor effects of chemotherapy in breast cancer patients.

Research center :

Giga-Cancer - ULiège

Disciplines :

Oncology

Author, co-author :

FRERES, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

JOSSE, Claire ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Bovy, Nicolas ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire

Boukerroucha, Meriem

Struman, Ingrid ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire

BOURS, Vincent ; Centre Hospitalier Universitaire de Liège - CHU > Génétique

JERUSALEM, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Language :

English

Title :

Neoadjuvant chemotherapy in breast cancer induces miR-34a and miR-122 expression

Alternative titles :

[fr] La chimiothérapie néoadjuvante dans le cancer du sein induit l'expression de miR-34a et miR-122

Publication date :

30 July 2014

Journal title :

Journal of Cellular Physiology

ISSN :

0021-9541

eISSN :

1097-4652

Publisher :

Wiley Liss, Inc., New York, United States - New York

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://onlinelibrary.wiley.com/doi/10.1002/jcp.24730/abstract

Name of the research project :

Circulating miRNAs as diagnostic, prognostic and predictive markers in breast cancer patients

Funders :

F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]

Available on ORBi :

since 19 August 2014

Statistics

Number of views

113 (41 by ULiège)

Number of downloads

14 (13 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Ambros V. 2004. The functions of animal microRNAs. Nature 431:350-355.
Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297.
Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavaré S, Caldas C, Miska EA. 2007. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8:1-16.
Bleyer A, Welch HG. 2012. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367:1998-2005.
Boominathan L. 2010. The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS ONE 5:1-13.
Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S, Kaluza D, Tréguer K, Carmona G, Bonauer A, Horrevoets AJG, Didier N, Girmatsion Z, Biliczki P, Ehrlich JR, Katus HA, Müller OJ, Potente M, Zeiher AM, Hermeking H, Dimmeler S. 2013. MicroRNA-34a regulates cardiac ageing and function. Nature 495:107-110.
Brase JC, Wuttig D, Kuner R, Sültmann H. 2010. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 9:1-9.
Chen X, Ba Y, Ma, L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. 2008. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997-1006.
Chiyomaru T, Yamamura S, Fukuhara S, Yoshino H, Kinoshita T, Majid S, Saini S, Chang I, Tanaka Y, Enokida H, Seki N, Nakagawa M, Dahiya R. 2012. Genistein Inhibits Prostate Cancer Cell Growth by Targeting miR-34a and Oncogenic HOTAIR. PLoS ONE 8:1-10.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE, Pazdur R, Ditsch N, Rastogi P, Eiermann W, Minckwitz von G. 2014. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet doi: 10.1016/S0140-6736(13) 62422-8.
Du T. 2005. microPrimer: the biogenesis and function of microRNA. Development 132:4645-4652.
Dvinge H, Git A, Gräf S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, Chin SF, Provenzano E, Turashvili G, Green A, Ellis I, Aparicio S, Caldas C. 2013. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497:378-382.
Eulalio A, Huntzinger E, Izaurralde E. 2008. Getting to the Root of miRNA-Mediated Gene Silencing. Cell 132:9-14.
Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. 2005. Cardiotoxicity of cancer therapy. J Clin Oncol 23:7685-7696.
Friedman RC, Farh K, Burge CB. 2009. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19:92-105.
Ghawanmeh T, Thunberg U, Castro J, Murray F, Laytragoon-Lewin N. 2010. miR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, docetaxel or combination treatment. Oncology 81:330-335.
He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. 2007. A microRNA component of the p53 tumour suppressor network. Nature 447:1130-1134.
Hermeking H. 2009. The miR-34 family in cancer and apoptosis. Cell Death Differ 17:193-199.
Hsu SD, Chu CH, Tsou AP, Chen SJ, Chen HC, Hsu PWC, Wong YH, Chen YH, Chen GH, Huang HD. 2007. miRNAMap 2.0: Genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res 36:D165-D169.
Hu J, Xu Y, Hao J, Wang S, Li C, Meng S. 2012a MiR-122 in hepatic function and liver diseases. Protein Cell 3:364-371.
Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao Y, Tang J, Chen X, Dai J, Wei Q, Zhang C, Shen H. 2012b Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis 33:828-834.
Javeri A, Ghaffarpour M, Taha MF, Houshmand M. 2013. Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis. Med Oncol 30:1-10.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA: Cancer J Clin 61:69-90.
John-Aryankalayil M, Palayoor ST, Makinde AY, Cerna D, Simone CB, Falduto MT, Magnuson SR, Coleman CN. 2012. Fractionated radiation alters oncomir and tumor suppressor miRNAs in human prostate cancer cells. Radiat Res 178:105-117.
Kosaka N, Iguchi H, Ochiya T. 2010. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101:2087-2092.
Kozomara A, Griffiths-Jones S. 2010. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39:D152-D157.
Kroh EM, Parkin RK, Mitchell PS, Tewari M. 2010. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50:298-301.
Li H, Yu G, Shi R, Bin Lang Chen X, Xia D, Xiao H, Guo X, Guan W, Ye Z, Xiao W, Xu H. 2013. Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy. Mol Cancer 13:1-13.
Li L, Xie X, Luo J, Liu M, Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z, Tang J, Wang X, Wei W, Yang M, Hung MC, Xie X. 2012. Targeted Expression of miR-34a Using the T-VISA System Suppresses Breast Cancer Cell Growth and Invasion. Mol Ther 20:2326-2334.
Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. 1994. p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. 2005. MicroRNA expression profiles classify human cancers. Nature 435:834-838.
Manfè V, Biskup E, Rosbjerg A, Kamstrup M, Skov AG, Lerche CM, Lauenborg BT, Odum N, Gniadecki R. 2012. miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. PLoS ONE 7:1-11.
Mathivanan S, Ji H, Simpson RJ. 2010. Exosomes: Extracellular organelles important in intercellular communication. J Proteomics 73:1907-1920.
Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, Vandesompele J. 2009. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10:1-10.
Mieog JSD, van der Hage JA, van de Velde CJH. 2006. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev CD005002-CD005002 doi: 10.1002/14651858.CD005002.pub2.
Minckwitz von G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S. 2012. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. J Clin Oncol 30:1796-1804.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen, BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. 2008. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513-10518.
Peurala H, Greco D, Heikkinen T, Kaur S, Bartkova J, Jamshidi M, Aittomäki K, Heikkilä P, Bartek J, Blomqvist C, Bützow R, Nevanlinna H. 2011. MiR-34a Expression Has an Effect for Lower Risk of Metastasis and Associates with Expression Patterns Predicting Clinical Outcome in Breast Cancer. PLoS ONE 6:1-10.
Pigati L, Yaddanapudi SCS, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML, Duelli DM. 2010. Selective Release of MicroRNA Species from Normal and Malignant Mammary Epithelial Cells. PLoS ONE 5:1-13.
Schmittgen TD, Livak KJ. 2007. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101-1108.
Stankevicins L, Almeida da Silva AP, Ventura Dos Passos F, Santos Ferreira Dos E, Menks Ribeiro MC, G David M, J Pires E, Ferreira-Machado SC, Vassetzky Y, de Almeida CE, de Moura Gallo CV. 2013. MiR-34a is up-regulated in response to low dose, low energy X-ray induced DNA damage in breast cells. Radiat Oncol 8:1-8.
Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. 2007. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A 104:15472-15477.
Turchinovich A, Samatov TR, Tonevitsky AG, Burwinkel B. 2013. Circulating miRNAs: cell-cell communication function? Front Genet 4:1-10.
Wang B, Wang H, Yang Z. 2011. MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R. PLoS ONE 7:1-9.
Wang X, Dong K, Gao P, Long M, Lin F, Weng Y, Ouyang Y, Ren J, Zhang H. 2013. microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status. Cancer Biother Radiopharm 28:45-50.
Wu X, Somlo G, Yu Y, Palomares MR, Li A, Zhou W, Chow A, Yen Y, Rossi JJ, Gao H, Wang J, Yuan YC, Frankel P, Li S, Ashing-Giwa K, Sun G, Wang Y, Smith R, Robinson K, Ren X, Wang S. 2011. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med 10:1-10.
Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. 2009. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE 5:1-12.